- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 154854 |
| Antigen/Gene or Protein Targets | Androgen Receptor variants |
| Parental Line | CWR22Rv1 |
| Synonyms | AR-V |
| Host | Human |
| Disease Keywords | Prostate Cancer |
| Model | Knock-In |
| Relevance |
Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression. Our understanding of how AR-Vs function is limited due to difficulties in distinguishing their discriminate activities from full-length AR (FL-AR). The CWR22Rv1-AR-EK (Androgen Receptor-Exon Knockout) cell line is a prostate cancer cell line which is knockout for FL-AR (by CRISPR) but retains expression of all endogenous AR-Vs making it a valuable model for the study of receptor splice variants. This new derivative is dependent upon AR-Vs for growth and is refractory to all FL-AR-targeting agents. |
| Production Details | CRISPR-derived cell line that has lost expression of full length androgen receptor (FL-AR), but retains all endogenous androgen receptor variants (AR-Vs). Two gRNAs were designed to target distinct loci within exon 5 of the AR gene. To knock-in a stop codon into exon 5 of the AR locus, a 180 bp ssODN template was designed containing a central TAA sequence and flanked by 75 bp 5′ and 3′ termini 100% complementary to the AR gene sequence. |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | RPMI 1640 media supplemented with 10% foetal calf serum (FCS) and 5% L-glutamine at 37°C |
| Notes |
CRISPR edited CWR22Rv1 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license. |
References: 1 entry
References: 1 entry
Inventor Information
Inventors
|
Dr Luke Gaughan |
